Akums Drugs and Pharmaceuticals Ltd
Ticker: AKUMS
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
463.45
Market Cap
7095.51
Debt/Equity
0.0288
ROE %
17.874
PB
2.3161
Promoter %
75.260
Pledge %
0.000
1Y Rev Growth %
-0.599
5Y Rev Growth %
11.389
NP Margin %
8.077
NP Margin 5Y Avg %
1.630
Trading Reference
1M Return %
-1.278
6M Return %
-2.871
1Y Return %
-47.371
% Away 52W High
102.816
% Away 52W Low
14.432
Daily Volume
117379
Investment Verdict
Hold
Score 71/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 20/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Akums Drugs and Pharmaceuticals Ltd is currently trading near a key support level, with the 50-day EMA indicating a bullish trend. If the stock breaks above the resistance level, there is potential for a significant upside. However, if it falls below the support, downside risk is present.
Upside Probability: 15% | Downside Probability: 10%
Probability estimates are technical-context statements, not investment advice.
More Options
D
Dhanuka Agritech Ltd
Dhanuka Agritech Ltd shows decent potential with consistent growth and profitability metrics, but faces challenges in execution and liquidity.
View details
P
Piccadily Agro Industries Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
C
CMS Info Systems Ltd
CMS Info Systems Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
K
Kovai Medical Center and Hospital Ltd
Kovai Medical Center and Hospital Ltd shows potential for growth but faces several risks and challenges that could impact its performance.
View details
T
Tamilnad Mercantile Bank Ltd
While Tamilnad Mercantile Bank has some growth potential, it faces challenges in profitability and execution risks, making it a cautious investment.
View details
T
Thangamayil Jewellery Ltd
Thangamayil Jewellery Ltd shows potential but faces challenges in profitability and execution risks.
View details
C
Chemplast Sanmar Ltd
Chemplast Sanmar Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and valuation metrics.
View details
B
Bajaj Electricals Ltd
Bajaj Electricals Ltd shows potential in a growing sector, but faces challenges in execution and competition. Investors should be cautious and monitor performance closely.
View details
K
Karnataka Bank Ltd
Karnataka Bank Ltd shows potential but faces significant challenges in growth and market sentiment, making it a risky investment at this time.
View details
N
National Highways Infra Trust
While National Highways Infra Trust operates in a crucial sector with growth potential, it faces several risks that could impact its performance. Caution is advised for investors.
View details
A
Axiscades Technologies Ltd
Axiscades Technologies Ltd shows potential but faces challenges in growth consistency and profitability metrics.
View details
S
Shree Renuka Sugars Ltd
Shree Renuka Sugars Ltd shows potential but is hindered by market volatility and governance concerns.
View details
B
BHARAT Bond ETF-April 2030-Growth
The Bharat Bond ETF has a decent score reflecting moderate growth potential and stability, but it faces challenges in execution and liquidity.
View details
A
Aurionpro Solutions Ltd
Aurionpro Solutions Ltd shows potential but faces challenges in growth consistency and valuation. Caution is advised.
View details
J
JK Paper Ltd
JK Paper Ltd shows decent growth potential but faces challenges in profitability and valuation metrics.
View details
J
Juniper Hotels Ltd
Juniper Hotels Ltd shows potential but faces significant challenges in profitability and valuation metrics.
View details
Business Overview
Akums Drugs and Pharmaceuticals Ltd is a leading Indian pharmaceutical manufacturer specializing in contract manufacturing and development of a wide range of pharmaceutical products. Catering primarily to domestic and international markets, Akums plays a crucial role in enhancing healthcare accessibility. With a commitment to quality and innovation, the company contributes significantly to the pharmaceutical landscape in India, ensuring compliance with global standards. Akums is dedicated to improving patient outcomes through its diverse product portfolio.
- Leading contract manufacturer in India
- Wide range of pharmaceutical products
- Focus on quality and innovation
- Strong compliance with global standards
- Enhancing healthcare accessibility
- Significant contributor to India's pharma landscape
Investment Thesis
Akums Drugs and Pharmaceuticals Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. These factors position the company favorably in the evolving pharmaceutical landscape.
- Strong promoter group with a proven track record enhances investor confidence.
- Expanding digital services segment poised for robust growth, tapping into modern healthcare trends.
- Attractive valuation metrics compared to industry peers, offering potential for upside.
- Established market presence and diverse product portfolio bolster revenue stability.
- Focus on R&D and innovation positions Akums for long-term competitive advantage.
Opportunity vs Risk
Opportunities
- Growing demand for pharmaceuticals
- Strong export potential
- Government support for healthcare
- Innovative product pipeline
- Expanding distribution network
Risks ⚠️
- Regulatory changes impact
- Intense market competition
- Raw material price volatility
- Dependence on key clients
- Foreign exchange fluctuations
Peer Perspective
Akums Drugs trades at a discount to peers like Sun Pharmaceutical and Cipla, reflecting its growth potential. A rerating could occur if it achieves consistent margin stability and accelerates revenue growth.
Future Outlook
Akums Drugs and Pharmaceuticals Ltd is well-positioned for growth, driven by strong demand in the healthcare sector. However, successful execution of its expansion plans and effective cost control will be crucial to achieving sustainable profitability.
AI FAQs for Retail Users
- Q: What does Akums Drugs and Pharmaceuticals Ltd do?A: Akums is a leading manufacturer of pharmaceutical formulations and active pharmaceutical ingredients in India.
- Q: Is Akums Drugs listed on stock exchanges?A: Yes, Akums Drugs is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE).
- Q: What are the key products of Akums?A: Akums produces a wide range of formulations, including tablets, capsules, and injectables across various therapeutic segments.
- Q: How has Akums performed financially?A: For detailed financial performance, please refer to their quarterly and annual reports available on their website.
- Q: What is the company’s growth strategy?A: Akums focuses on expanding its product portfolio and increasing its presence in international markets.
📊 Stock Investment Checklist (100 Points)
Akums Drugs and Pharmaceuticals Ltd • Updated: 2025-09-17 01:09:07
-
10BusinessHighPharmaceutical sector is growing, but competition is intense.
-
10GrowthHighConsistent revenue growth, but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is fluctuating.
-
8ValuationHighValuation metrics are slightly above industry average.
-
7BalanceHighModerate debt levels, but liquidity is adequate.
-
6GovernanceGoodPromoter holding is strong, but some pledging exists.
-
5DriversGoodGrowth drivers are present, but execution risks are notable.
-
5TechnicalsGoodMarket sentiment is neutral with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
Akums Drugs and Pharmaceuticals Ltd shows potential for growth, but faces challenges in profitability and market competition.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 72/100